ClinSeq: A Large-Scale Medical Sequencing Clinical Research Pilot Study : ClinSeq: A Large-Scale Medical Sequencing Clinical Research Pilot Study
The purpose of ClinSeq is to research large-scale medical sequencing (LSMS) in a clinical research setting. It was developed at a time (approximately 2007) when little was known about the processes and outcomes of doing so. By conducting LSMS and returning individual results to participants, we intended to investigate some of the technical, medical, and genetic counseling issues that accompanied the implementation of LSMS in the clinical setting. Three of our objectives have been met and the relevant findings have largely been published including:Developing methods for recruiting and consenting a large, racially-diverse cohortContinuing to improve upon existing algorithms for generating and interpreting sequence dataBuild and offer this cohort as a resource for addressing biomedical research questions including investigating the association of genomic variants with traits and phenotypesHowever, there is still much to be learned regarding LSMS, much of which is pertinent to our original aim of improving our understanding of socio-behavioral aspects of implementation of LSMS in a clinical research setting. Remaining objectives include:To understand patient outcomes (e.g., health behavior, communication, personal utility, emotional) following the receipt of medically actionable results.To investigate the impact of an intervention designed to promote better understanding of theaccuracy of genetic sequencing among those consenting to LSMS.To investigate the outcomes of returning negative secondary findings reports via a website and compare two versions of a slide developed to improve women s understanding of their residual risk for breast cancer following the receipt of such a report.To identify genetic risk factors for diabetes and other metabolic diseases related to glucose metabolism..
Medienart: |
Klinische Studie |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
ClinicalTrials.gov - (2024) vom: 29. März Zur Gesamtaufnahme - year:2024 |
---|
Sprache: |
Englisch |
---|
Links: |
Volltext [kostenfrei] |
---|
Themen: |
610 |
---|
Anmerkungen: |
Source: Link to the current ClinicalTrials.gov record., First posted: December 12, 2006, Last downloaded: ClinicalTrials.gov processed this data on April 03, 2024, Last updated: April 03, 2024 |
---|
fisyears: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
CTG000105694 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | CTG000105694 | ||
003 | DE-627 | ||
005 | 20240403010456.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240320s2024 xx |||||o 00| ||eng c | ||
035 | |a (DE-627)CTG000105694 | ||
035 | |a (UBBS_Klinische_Studien)NCT00410241 | ||
035 | |a (UBBS_Klinische_Studien)070002 | ||
035 | |a (UBBS_Klinische_Studien)07-HG-0002 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
245 | 1 | 0 | |a ClinSeq: A Large-Scale Medical Sequencing Clinical Research Pilot Study |b ClinSeq: A Large-Scale Medical Sequencing Clinical Research Pilot Study |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Source: Link to the current ClinicalTrials.gov record., First posted: December 12, 2006, Last downloaded: ClinicalTrials.gov processed this data on April 03, 2024, Last updated: April 03, 2024 | ||
520 | |a The purpose of ClinSeq is to research large-scale medical sequencing (LSMS) in a clinical research setting. It was developed at a time (approximately 2007) when little was known about the processes and outcomes of doing so. By conducting LSMS and returning individual results to participants, we intended to investigate some of the technical, medical, and genetic counseling issues that accompanied the implementation of LSMS in the clinical setting. Three of our objectives have been met and the relevant findings have largely been published including:Developing methods for recruiting and consenting a large, racially-diverse cohortContinuing to improve upon existing algorithms for generating and interpreting sequence dataBuild and offer this cohort as a resource for addressing biomedical research questions including investigating the association of genomic variants with traits and phenotypesHowever, there is still much to be learned regarding LSMS, much of which is pertinent to our original aim of improving our understanding of socio-behavioral aspects of implementation of LSMS in a clinical research setting. Remaining objectives include:To understand patient outcomes (e.g., health behavior, communication, personal utility, emotional) following the receipt of medically actionable results.To investigate the impact of an intervention designed to promote better understanding of theaccuracy of genetic sequencing among those consenting to LSMS.To investigate the outcomes of returning negative secondary findings reports via a website and compare two versions of a slide developed to improve women s understanding of their residual risk for breast cancer following the receipt of such a report.To identify genetic risk factors for diabetes and other metabolic diseases related to glucose metabolism. | ||
650 | 2 | |a Heart Diseases | |
650 | 2 | |a Coronary Artery Disease | |
650 | 2 | |a Myocardial Ischemia | |
650 | 4 | |a Study Type: Observational | |
650 | 4 | |a Recruitment Status: Active, not recruiting | |
650 | 4 | |a 610 | |
773 | 0 | 8 | |i Enthalten in |t ClinicalTrials.gov |g (2024) vom: 29. März |
773 | 1 | 8 | |g year:2024 |g day:29 |g month:03 |
856 | 4 | 0 | |u https://clinicaltrials.gov/show/NCT00410241 |z kostenfrei |3 Volltext |
912 | |a GBV_CTG | ||
951 | |a AR | ||
952 | |j 2024 |b 29 |c 03 |